statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Companys manufacturing...

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

What the Options Market Tells Us About Teva Pharmaceutical Indus

Results from the Phase 3 SOLARIS trial of TEV-'749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed...

Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024. This press release features multimedia. View the full release here...

Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3...

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday...

Teva to Present at the 2024 Bank of America Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy planet and a healthy business. The...

Tevas 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva...

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab)

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Investment analysts at Zacks Research increased their Q3 2025 earnings estimates for shares of Teva Pharmaceutical Industries in a...

Q3 2025 EPS Estimates for Teva Pharmaceutical Industries Limited Raised by Zacks Research (NYSE:TEVA)

Lauren Clason | (TNS) CQ-Roll Call
A recent tweak to a Medicaid formula could be behind the shake-up to inhaler products, a series of changes that have both benefited and harmed patients with asthma...

Experts say Medicaid rebate change is behind inhaler price cuts

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Watchers	26,198
52-Wk Low	$7.09
52-Wk High	$17.13

Volume	16.65M
52-Wk High	$17.13
52-Wk Low	$7.09

Period	Estimated	Reported	Surprise	Result
Q2'24	$0.60	--	--	N/A
Q1'24	$0.51	$0.48	-6.58%	MISSED
Q4'23	$0.77	$1.00	30.29%	BEAT
Q3'23	$0.61	$0.60	-1.29%	MISSED
Q2'23	$0.53	$0.56	6.62%	BEAT

TEVA Teva- Pharmaceutical Industries Ltd. - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals